CLEVELAND, April 13 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BSE:CFB), announced today that Daniel Mallin, Ph.D. and Stephen Brozak of WBB Securities, LLC have initiated coverage on the Company.

The WBB Securities report, dated April 13, 2007, assigned a Buy rating to the Company, with a 12-month target price of $13.00. The report's introduction states, "BioShield Accelerates Drug Development." Interested parties should contact WBB Securities for more information about the report.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release does not suggest or imply an endorsement by the Company of any projection or recommendation included in any analyst report.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our filings with the Securities and Exchange Commission.

    The Global Consulting Group
    Rachel Levine
    T: (646) 284-9439